Predictors of Sexual Function Post-AMI in Young AdultsWhat outcomes do you expect from this study? One modifiable risk factor is actually in your hands.
Amiodarone: Top 3 Things to Know for Rate or Rhythm Control of AFAmiodarone effectively treats a wide range of tachycardias but should always be prescribed with caution. Here are 3 key points to remember.
AHA Statement on Heart Failure and PolypharmacyVIDEO: In a Medical News Minute, a topline review of the AHA's comprehensive guide to risk reduction in HF patients.
Managing Hypertension in CKD, Diabetes, and Heart Disease: It takes a VillageDrugs that improve blood pressure may have negative effects on a wide range of common comorbidities.
PAH Complicates Post-MI RV DysfunctionA new study assessed the poorly understood impact of pulmonary hypertension on mortality after myocardial infarction.
New HF Guidelines from the ESCThis short slide show highlights new drugs now recommended, a new HF category, and recommendations for optimizing treatment.
6 Cardiology Meeting HighlightsResearchers presented several new findings about statins and non-statins at ACC.16. This brief roundup summarizes these and other noteworthy reports.
CardioScience Update, 4 New StudiesHighlights of four recent studies in hypertension, heart failure, preeclampsia expose vulnerable populations.
PCSK9 Inhibitors Remarkable Drugs, Many UnknownsPCSK9-I Patient Population and Potential [1] FDA-approved for relatively small patient group w/ uncontrolled LDL despite max therapy and at high risk for CVD. Familial hypercholesterolemia: ~620,000 in US.
At Long Last, an Antidote for a NOAC!
At Long Last, an Antidote for a NOAC!One of the biggest advances in the world of nonvalvular atrial fibrillation was the introduction of the novel oral anticoagulants (NOACs) for decreasing thromboembolic risk.